| abstract |
The present invention is directed to a method identifying a risk for a thrombogenicndisorder including, without limitation, atrial fibrillation, stroke, prolonged intermittednneurological deficit (PRIND), transitory ischemic attack (TIA), atheroscleroticncerebrovascular disease (CVD) and/or coronary heart disease, as well as to anmethod for selecting patients with a risk for a thrombogenic disorder, to a method fornidentifying a pharmaceutical for the therapy or prophylaxis of a thrombogenicndisorder as well as to a method for producing a medicament and a diagnostic bynemploying the TAFI-Ile347 polymorphism. |